The Consortium of Multiple Sclerosis Centers Annual Meeting is the leading research and educational conference for multiple sclerosis healthcare professionals of all disciplines in North America.
Levels of GFAP Higher in NMOSD, Suggesting It May Serve as a Biomarker
May 28th 2020A subset group of inebilizumab-treated patients who did not have adjudicated attacks displayed more than a 2-fold increase in serum CSF glial fibrillary acidic protein from baseline, implying GFAP may serve as a biomarker.
Ofatumumab Increases NEDA-3 Likelihood in MS Compared With Teriflunomide
May 26th 2020Novartis’s anti-CD20 monoclonal antibody has been shown to increase the odds of patients with multiple sclerosis achieving no evidence of disease activity status by more than 3-fold in the first year and more than 8-fold in the second year.
Making MS Therapy Decisions in an Ever-Evolving Treatment Landscape
July 4th 2019The MS neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the impact that propensity score has had on real-world data analysis, the use of additional outcome measures in trials, and the increasing understanding of progressive disease.
Amy B. Sullivan, PsyD: Screening MS Patients for Comorbidities
June 21st 2019The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of screening patients with MS for other conditions for which they are prevalently comorbid, such as depression or sleep disorders.
Laura T. Safar, MD: Carefully Addressing Mental Health in MS
June 18th 2019The director of MS neuropsychiatry at Brigham and Women’s Hospital spoke of the importance of not oversimplifying the approach to mental health disorders in individuals with MS, and how the collaborative care model can help.­­­
Emily Splichal, DPM: Using Texture for Nerve Stimulation in the Feet
June 13th 2019Many patients with neurologic conditions such as multiple sclerosis are faced with gait and stability issues due to their disease, but Splichal and Naboso Technology seek to address these issues via mechanoreceptor stimulation.